BioPhorum and Rx-360 join forces with the BSI to alleviate the supplier audit burden and give pharma companies control
Cross-industry collaboration BioPhorum and Rx-360 have agreed a pilot to validate the use of the Joint Audit Model in the single-use systems supply chain.
In a statement, the group said that the British Standards Institute (BSI) is set to conduct the pilot audits. The pilot is due to complete in October 2019.
The aim is to deliver consistent, rigorous and cost-effective quality audits, that will alleviate the supplier audit burden while ensuring biopharmaceutical manufacturers are in control of their supply chain.
Rx-360 is an international consortium that addresses pharmaceutical and medical device supply chain security that relates to public health concerns and patient safety.
A Steering Committee consisting of members from all three organisations will drive the pilot through the analysis of data and the implementation of best practices or improvements.
The pilot will identify ‘reviewers’ who will take on the traditional roles of co-sponsors of the audits, as described in the current Rx-360 Joint Audit Model.
The pilot will consist of 12 audits split into four sections of three audits.
Key measures that will be tracked during the pilot are:
Once completed, a team from BioPhorum and Rx-360 will publish a consensus paper in Q4 2019 detailing the results from the pilot.